WO2011076117A1 - 绝经期促性腺素组合物 - Google Patents
绝经期促性腺素组合物 Download PDFInfo
- Publication number
- WO2011076117A1 WO2011076117A1 PCT/CN2010/080097 CN2010080097W WO2011076117A1 WO 2011076117 A1 WO2011076117 A1 WO 2011076117A1 CN 2010080097 W CN2010080097 W CN 2010080097W WO 2011076117 A1 WO2011076117 A1 WO 2011076117A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- fsh
- composition according
- international units
- protein
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
Definitions
- the present invention relates to the field of protein purification and biomedicine.
- the present invention relates to a composition of menopausal gonadotropins and their stabilizers which have good stability. Background technique
- HMG Human Menopausal Gonadotropins
- FSH Follicle-stimulating hormone
- LH leute ini zing hormone
- Glycoprotein hormone which consists of two subunits, the alpha chain and the beta chain.
- the a subunit of FSH is identical to the alpha subunit of levo ini zing hormone (LH) and chorionic gonadotropin (CG), with 92 amino acids and a molecular weight of approximately 14500 D.
- Asparagine at positions 52 and 78 is an amino acid that undergoes glycosylation.
- the beta subunit of FSH consists of 111 amino acids with a molecular weight of approximately 18,000 D, wherein asparagine at positions 7 and 24 is an amino acid that undergoes /glycosylation. While the LH ⁇ -subunit consists of 121 amino acids, molecular weight of about 14800 D; CG of the ⁇ -subunit has 145 amino acids, molecular weight 22000-39000 DH.
- the bioavailability ratio of FSH and LH in HMG is between 10:1 and 1:10, usually 2:1 to 1: lo
- HMG is mainly used to treat infertility and assisted reproduction in vitro.
- HMG can be extracted from the urine of menopausal women, and FSH and LH can also be prepared by DNA recombination techniques.
- the preparation form of HMG is usually a lyophilized powder needle, which is administered by intramuscular injection.
- High-purity menopausal gonadotropin (pHMG) is a successor of HMG, which is a product with high purity and low impurity obtained by further purifying HMG to remove a large amount of heteroprotein, so it does not cause an allergic reaction in human body, and Because of these advantages, it can be used for subcutaneous injection, improve patient compliance, facilitate patient use, and alleviate pain.
- the form of pHMG can be lyophilized powder needle or water needle.
- W02004087213 discloses formulations containing HMG, sucrose and the surfactant Pluroni c and L-methionine. Although the above three formulations are relatively stable, the addition of various surfactants and excipients poses a great potential for the safety of the formulation.
- the present invention is directed to a pharmaceutical composition comprising a menopausal gonadotropin comprising a high purity menopausal gonadotropin.
- a protein composition comprising: menopausal gonadotropin (HMG) and / or a variant thereof, and sucrose.
- the composition is in liquid form or in solid form.
- the solid form is a freeze-dried powder.
- the solid form of the composition comprises 0.1-200 FSH international units per mg of the composition, based on the FSH bioavailability.
- the solid form of the composition contains 0.5 to 50 FSH international units per mg of the composition.
- the solid form of the composition contains 1-20 FSH international units per mg of the composition based on the FSH bioavailability.
- the composition in liquid form contains from 1 to 2000 FSH International Units per mL of composition, based on FSH bioavailability.
- liquid form of the composition is contained in terms of FSH biological potency
- the biopotency ratio of follic sputum hormone (FSH) to luteinizing hormone (LH) ranges from 10:1 to 1:10. Preferably, it is between 3:1 and 1:2; more preferably between 2:1 and 1:1.
- the composition contains a menopausal gonadotropin which is a high-purity menopausal gonadotropin (pHMG) having a specific activity of not less than 5000 FSH international units/mg protein; more preferably a specific activity Do not Less than 6000 FSH international units / mg protein; more preferably, the specific activity is not less than 8000 FSH international units / mg protein.
- pHMG menopausal gonadotropin
- the composition contains menopausal gonadotropins from human urine-derived menopausal gonadotropins and/or variants thereof.
- composition may further comprise a pharmaceutically acceptable carrier;
- pharmaceutically acceptable carrier may be selected from one or more of the following: pH adjusting agent, non- Ionic surfactants, preservatives, salts, disaccharides, mannitol.
- the pH adjusting agent is a phosphate.
- composition of the present invention is obtained by plugging, sealing or freeze-drying, followed by tamping and sealing.
- the pH of the aqueous solution in the step (1) is from 6. 0 to 8. 5; preferably from 6. 5 to 8. 0.
- the present invention provides a form of preparation of a menopausal gonadotropin having good stability, ease of use, and safety and efficacy.
- sucrose at this time acts not only as a diluent and an excipient, but more importantly as a protective agent, which protects the conformational changes that may occur during storage and subsequent storage of glycoprotein molecules.
- the resulting degeneration is deactivated. On the other hand, it also greatly improves the stability of the product.
- the inventors have completed the present invention.
- "menopausal gonadotropin”, “urinary gonadotropin” and “HMG” are used interchangeably and refer to a class of glycoprotein hormones or variants thereof produced by the pituitary, containing both FSH and LH. Active ingredient. It may be a recombinant menopausal gonadotropin or a variant thereof, or a human urine-derived menopausal gonadotropin or a variant thereof.
- follicle stimulating hormone and “FSH” are used interchangeably and refer to a class of hormones or variants thereof that promote sperm or follicle production, promote ovarian development, which can be naturally preceded by the pituitary gland.
- Leaf secretion can be extracted from the urine of menopausal women or can be obtained by recombinant techniques.
- Luteinizing hormone and “LH” are used interchangeably to refer to a type of hormone that is secreted by the basal cells of the anterior pituitary gland and acts on mature oocytes to cause ovulation and produce corpus luteum. Or its variants.
- impurity refers to substances other than menopaus gonadotropins, and refers to heteroproteins other than FSH, LH, such as degradation subunits, polymeric subunits, and the like.
- sucrose acts as a protective agent to prevent denaturation of the glycoprotein molecules due to conformational changes that may occur during lyophilization and subsequent storage.
- compositions provided herein contain menopausal gonadotropins; sucrose; and/or a pharmaceutically acceptable carrier.
- the sum of the weights of sucrose and menopausal gonadotropin is from 6 to 100%, preferably from 80 to 99%, more preferably from 90 to 98%, based on the total weight of the composition.
- the content is in the range of 0.1-200 FSH international units, preferably 0.5-50 FSH international units, more preferably in the FSH bio-potency. For the 1-20 FSH International Unit.
- the FSH bioavailability is in the range of 1-2000 FSH international units, preferably 30-1000 FSH international units.
- the weight ratio of menopausal gonadotropin to sucrose is 0.00001: 1 - 1: 1, preferably 0.0001: 1 - 0.01: 1.
- the ratio of the biopotency of follic sputum hormone (FSH) to luteinizing hormone (LH) is between 10:1 and 1:10; It is between 3:1 and 1:2; more preferably between 2:1 and 1:1.
- FSH follic sputum hormone
- LH luteinizing hormone
- puri fi ed Human Menopausal Gonadotropins (pHMG) refers to HMG that is more than 5000 FSH international units (IU) / mg protein, preferably live at 6000 FSH IU. Above /mg protein, more preferably than 8000 FSH IU/mg protein.
- the term "pharmaceutically acceptable carrier” refers to a carrier for the administration of a therapeutic agent, including various excipients and diluents.
- the term refers to pharmaceutical carriers which are not themselves essential active ingredients and which are not excessively toxic after administration. Suitable carriers are well known to those of ordinary skill in the art. A full discussion of pharmaceutically acceptable excipients can be found in Remington's Pharmaceut i cal Sc ences (Mack Pub. Co., N. J. 1991).
- the pharmaceutically acceptable carrier in the composition may include liquids such as water, saline, glycerol and ethanol.
- auxiliary substances such as disintegrants, wetting agents, emulsifiers, pH buffering substances and the like may also be present in these carriers.
- compositions can be prepared in a variety of dosage forms depending on the route of administration. These dosage forms are administered in one of the following ways: oral, spray inhalation, rectal administration, nasal administration, buccal administration, topical administration, parenteral administration, such as subcutaneous, intravenous, intramuscular, intraperitoneal, intrathecal, intraventricular, intrasternal And intracranial injection or input, or with an explant reservoir. Among them, subcutaneous or muscle administration is preferred in the treatment.
- the dosage and method of use of the active ingredient in the pharmaceutical composition of the present invention depends on various factors including the age, weight, sex, natural health status, nutritional status of the active ingredient, the intensity of active ingredient activity, the rate of taking, the rate of metabolism, and the condition.
- the severity of the diagnosis and the subjective judgment of the doctor is recommended, typically at least about 30 FSH international units per day, and in most cases no more than about 600 FSH international units per day, preferably about 75 - 450 FSH international units. /day.
- specific doses should also consider factors such as the route of administration, the health of the patient, etc., which are within the skill of the skilled physician.
- the compositions provided by the present invention have good stability.
- the stable pharmaceutical composition of the present invention can be prepared by first dissolving phosphate and sucrose in water, then adding menopausal gonadotropin, stirring uniformly, tamping, sealing or freeze-drying, followed by tamping and sealing.
- a composition of menopausal gonadotropin is provided for easy storage and transportation;
- the pharmaceutical composition of the menopausal gonadotropin obtained by the method of the present invention has good stability.
- the invention is further illustrated below in conjunction with specific embodiments. It is to be understood that the examples are not intended to limit the scope of the invention.
- the experimental methods in which the specific conditions are not indicated in the following examples are usually carried out according to conventional conditions or according to the conditions recommended by the manufacturer. Percentages and parts are by weight unless otherwise stated.
- Method for determination of protein content The measurement was carried out according to the Lowry method.
- menopausal gonadotropin HMG
- FSH biopotency 330 IU/mg
- FSH specific activity 475 IU/mg
- the protein, LH biopotency was 306 IU/mg
- the LH specific activity was 440 IU/mg protein.
- a, shelf temperature is +4 ° C for 20 minutes
- the shelf temperature is reduced to below -40 °C for 3 hours;
- the degree of vacuum is turned on, and the degree of vacuum is reduced to less than lOOmTor;
- high-purity menopausal gonadotropin (pHMG) was purchased from Shanghai Tianwei Bio-Pharmaceutical Co., Ltd., and its FSH bio-potency was 7530 IU/mg, and the FSH specific activity was 10,750 IU. /mg protein, LH biopotency is 7709 IU/mg, and LH specific activity is 11006 IU/mg protein.
- Example 3 The materials used in Example 3 and Comparative Example 3 were the same as in Example 2.
- Control Formulation 3 containing 75 IU of FSH and 75 IULH (Formula disclosed in US 5,650,390) pHMG 12.5 ⁇ g
- the preparation method is the same as that in the example 1 of the control formulation containing 75 IU of FSH and 75 IU of LH (the formulation disclosed in W02004112826A1):
- the preparation method was the same as in Example 1.
- Example 4 The materials used in Example 4 and Comparative Example 4 were the same as in Example 2.
- Control Formulation 5 containing 75 IU FSH and 75 IU LH (as disclosed in WO2004087213 with pHMG 12.5 ⁇ g)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020127019133A KR101483165B1 (ko) | 2009-12-22 | 2010-12-22 | 인간폐경성선자극호르몬의 조성물 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910201566.X | 2009-12-22 | ||
CN200910201566 | 2009-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011076117A1 true WO2011076117A1 (zh) | 2011-06-30 |
Family
ID=44154108
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2010/080097 WO2011076117A1 (zh) | 2009-12-22 | 2010-12-22 | 绝经期促性腺素组合物 |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR101483165B1 (zh) |
CN (1) | CN102100908B (zh) |
WO (1) | WO2011076117A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102293756A (zh) * | 2011-08-24 | 2011-12-28 | 蚌埠丰原涂山制药有限公司 | 一种尿促性素冻干粉针剂及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004087213A1 (en) * | 2003-04-02 | 2004-10-14 | Ares Trading S.A. | Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant |
WO2004112826A1 (en) * | 2003-06-20 | 2004-12-29 | Ares Trading Sa | Freeze-dried fsh / lh formulations |
CN101851287A (zh) * | 2009-04-02 | 2010-10-06 | 上海天伟生物制药有限公司 | 一种高比活绝经期促性腺素及其制备方法和用途 |
CN101928342A (zh) * | 2009-06-18 | 2010-12-29 | 上海天伟生物制药有限公司 | 一种高纯度绝经期促性腺素及其制备方法和用途 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1250075B (it) * | 1991-12-18 | 1995-03-30 | Serono Cesare Ist Ricerca | Composizioni farmaceutiche contenenti gonadotropine. |
FR2849380A1 (fr) | 2002-12-27 | 2004-07-02 | Ernest Loumaye | NOUVELLE UTILISATION D'UN AGONISTE DU GnRH |
CN101269215B (zh) * | 2008-05-15 | 2011-03-23 | 上海天伟生物制药有限公司 | 一种糖蛋白激素组合物 |
-
2010
- 2010-12-22 KR KR1020127019133A patent/KR101483165B1/ko active IP Right Grant
- 2010-12-22 WO PCT/CN2010/080097 patent/WO2011076117A1/zh active Application Filing
- 2010-12-22 CN CN2010106177543A patent/CN102100908B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004087213A1 (en) * | 2003-04-02 | 2004-10-14 | Ares Trading S.A. | Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant |
WO2004112826A1 (en) * | 2003-06-20 | 2004-12-29 | Ares Trading Sa | Freeze-dried fsh / lh formulations |
CN101851287A (zh) * | 2009-04-02 | 2010-10-06 | 上海天伟生物制药有限公司 | 一种高比活绝经期促性腺素及其制备方法和用途 |
CN101928342A (zh) * | 2009-06-18 | 2010-12-29 | 上海天伟生物制药有限公司 | 一种高纯度绝经期促性腺素及其制备方法和用途 |
Also Published As
Publication number | Publication date |
---|---|
CN102100908B (zh) | 2013-05-08 |
CN102100908A (zh) | 2011-06-22 |
KR20120106850A (ko) | 2012-09-26 |
KR101483165B1 (ko) | 2015-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI118208B (fi) | Monomeeriset insuliinianalogivalmisteet | |
KR100221123B1 (ko) | 안정화된 고나도트로핀을 함유하는 제제 | |
JP4255515B2 (ja) | 安定化された成長ホルモン処方物およびその製造方法 | |
JP2005537232A (ja) | アミリンアゴニストペプチドの製剤 | |
TWI755377B (zh) | 穩定的液態促性腺激素調配物 | |
KR20080106636A (ko) | 사람 융모성 성선자극호르몬 함유 즉시 사용형 주사 용액 | |
US8871713B2 (en) | Formulations of growth hormone releasing factor (GRF) molecules with improved stability | |
JP4699991B2 (ja) | 非イオン性界面活性剤を一緒に伴うfsh及びlhの液体医薬組成物 | |
KR20090123863A (ko) | 췌장 당뇨병 치료용 엑세나티드 및 달라르긴-기반 약학적 제제 | |
US8058236B2 (en) | Aqueous inhalation pharmaceutical composition | |
WO2011076117A1 (zh) | 绝经期促性腺素组合物 | |
JP5143784B2 (ja) | 糖タンパク質ホルモン組成物 | |
AU778208C (en) | GRF-containing lyophilized pharmaceutical compositions | |
US20230270865A1 (en) | Low-dose pharmaceutical compositions of ghrh analogs and uses thereof | |
WO2023231730A2 (zh) | 使用mazdutide的治疗方法 | |
WO2010031262A1 (zh) | 几乎不含亚基的糖蛋白的组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10838680 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20127019133 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6390/CHENP/2012 Country of ref document: IN |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10838680 Country of ref document: EP Kind code of ref document: A1 |